667 related articles for article (PubMed ID: 29615111)
1. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).
Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S
Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
[TBL] [Abstract][Full Text] [Related]
3. Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project.
Morbelli S; Perneczky R; Drzezga A; Frisoni GB; Caroli A; van Berckel BN; Ossenkoppele R; Guedj E; Didic M; Brugnolo A; Naseri M; Sambuceti G; Pagani M; Nobili F
J Nucl Med; 2013 Jun; 54(6):894-902. PubMed ID: 23591639
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
[TBL] [Abstract][Full Text] [Related]
5. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
[TBL] [Abstract][Full Text] [Related]
6. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
8. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
[TBL] [Abstract][Full Text] [Related]
9. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.
Arbizu J; Prieto E; Martínez-Lage P; Martí-Climent JM; García-Granero M; Lamet I; Pastor P; Riverol M; Gómez-Isla MT; Peñuelas I; Richter JA; Weiner MW;
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1394-405. PubMed ID: 23715905
[TBL] [Abstract][Full Text] [Related]
10. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
[TBL] [Abstract][Full Text] [Related]
11. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
[TBL] [Abstract][Full Text] [Related]
12. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings.
Pagani M; Dessi B; Morbelli S; Brugnolo A; Salmaso D; Piccini A; Mazzei D; Villavecchia G; Larsson SA; Rodriguez G; Nobili F
Curr Alzheimer Res; 2010 Jun; 7(4):287-94. PubMed ID: 19939228
[TBL] [Abstract][Full Text] [Related]
13. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
14. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia.
Huang SH; Hsiao WC; Chang HI; Ma MC; Hsu SW; Lee CC; Chen HJ; Lin CH; Huang CW; Chang CC
BMC Med Imaging; 2024 Mar; 24(1):75. PubMed ID: 38549082
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.
Lange C; Suppa P; Pietrzyk U; Makowski MR; Spies L; Peters O; Buchert R;
J Alzheimers Dis; 2018; 61(1):373-388. PubMed ID: 29154285
[TBL] [Abstract][Full Text] [Related]
16. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Outcomes in Mild Cognitive Impairment by Using 18F-FDG-PET: A Multicenter Study.
Ito K; Fukuyama H; Senda M; Ishii K; Maeda K; Yamamoto Y; Ouchi Y; Ishii K; Okumura A; Fujiwara K; Kato T; Arahata Y; Washimi Y; Mitsuyama Y; Meguro K; Ikeda M;
J Alzheimers Dis; 2015; 45(2):543-52. PubMed ID: 25589723
[TBL] [Abstract][Full Text] [Related]
18. Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment.
Apostolova I; Lange C; Suppa P; Spies L; Klutmann S; Adam G; Grothe MJ; Buchert R;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1417-1422. PubMed ID: 29502311
[TBL] [Abstract][Full Text] [Related]
19. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
Ota K; Oishi N; Ito K; Fukuyama H; ;
J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
